Technavio has published a new report on the drug development pipeline for anal cancer, including a detailed study of the pipeline molecules. (Graphic: Business Wire)
Technavio has announced their latest pipeline analysis report on the anal cancer market. The report includes a detailed analysis of the pipeline molecules under investigation within the defined data collection period to treat anal cancer.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180630005046/en/
Technavio has published a new report on the drug development pipeline for anal cancer, including a detailed study of the pipeline molecules. (Graphic: Business Wire)
This report is available at a USD 1,000 discount for a limited time only: View market snapshot before purchasing
Anal cancer: Market overview
Anal cancer is an abnormal malignant cell growth in the tissues of the anus, the distal opening of the gastrointestinal tract. These cell growths are largely caused by human papillomavirus. Early growth of HPV is sometimes harmless and can be cured if treated on time; on the other hand, it can develop into cancer as well. HPV is usually a sexually transmitted disease and is a major cause of anal cancer.
According to a senior analyst at Technavio, “The human body constantly makes new cells and helps them to grow. Cancer is developed when the cells do not grow, and divide in their usual way and tend to form a lump called tumor. Anal cancer can be divided into two parts, cancers of the anal canal and cancers of the anal margin.”
Anal cancer: Segmentation analysis
This market research report segments the anal cancer market based on therapies employed that includes monotherapy, combination therapy, and monotherapy/combination therapy , RoA (intravenous, subcutaneous, intravenous + oral, subcutaneous + intradermal, and unknown), therapeutic modalities (vaccine, monoclonal antibody, and small molecules), targets for drugs under development (PD1, HPV16 E7 protein, CDK, T-cell, EGFR, and unknown), MoA (PD1 inhibitor, HPV16 E7 protein modulator, HPV16 E7 protein inhibitor, CDK inhibitor, T-cell killer, EGFR inhibitor, and unknown), drugs under development (phase I, phase I/II, and phase II), and recruitment status (recruiting, completed, active not recruiting, and unknown). It provides an in-depth analysis of the prominent factors influencing the market, including drivers, opportunities, trends, and industry-specific challenges.
Looking for more information on this market? Request a free sample report
Technavio’s sample reports are free of charge and contain multiple sections of the report such as the market size and forecast, drivers, challenges, trends, and more.
Some of the key topics covered in the report include:
Scope of the Report
Regulatory Framework
Drug Development Landscape
Drug Development Strategies
Recruitment Strategies
Key Companies
Discontinued or Dormant Molecules
About Technavio
Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
If you are interested in more information, please contact our media team at media@technavio.com.
View source version on businesswire.com:
Technavio Research
Jesse Maida
Media & Marketing Executive
US:
+1 844 364 1100
UK: +44 203 893 3200
www.technavio.com